Research suggests that increased tumor glycolysis is linked to decreased immune infiltration in human solid tumors. Studies have investigated this relationship in various types of cancer, including breast, colorectal, and lung cancer, and have identified potential biomarkers and therapeutic targets. The findings imply a complex interplay between tumor metabolism and immune function, with possible implications for cancer therapy.